#United States #Redwood City #siRNA #Codexis #ECO Synthesis

Codexis Teams Up to Advance RNA Therapeutics Manufacturing

On March 4, 2026, in Redwood City, California, Codexis, Inc., a trailblazer in enzymatic solutions for therapeutic manufacturing, announced a significant agreement with an innovative pharmaceutical company. The collaboration aims to produce 50 grams of small interfering RNA (siRNA), which will be facilitated through Codexis's proprietary ECO Synthesis® Manufacturing Platform. This strategic partnership is designed to bolster the preclinical development of a promising therapeutic candidate focused on cardiovascular diseases.

The Significance of siRNA in Cardiovascular Therapies

siRNA plays a critical role in gene silencing, offering a potential treatment avenue for a variety of conditions, including cardiovascular disorders. By targeting and silencing specific genes associated with disease processes, siRNA therapeutics can help mitigate cardiovascular diseases that affect millions globally. The production of siRNA in larger quantities allows researchers to thoroughly evaluate its effectiveness, leading to advancements in therapeutic applications.

The Role of the ECO Synthesis Manufacturing Platform

Codexis's ECO Synthesis platform is specially engineered for the efficient and high-fidelity production of complex siRNA therapeutics. As RNA therapeutics evolve from niche applications targeting rare diseases to broader indications, the need for scalable manufacturing options has become paramount. Codexis believes that its ECO Synthesis technology is uniquely positioned to meet these growing demands, offering an effective pathway for increasing production capability without compromising the quality of the finished product.

Commitment to Quality and Efficiency

Under the terms of the agreement, Codexis will be responsible for supplying siRNA material crucial to its partner's preclinical program. This partnership symbolizes an important step forward in demonstrating the scalability of Codexis's manufacturing capabilities, as it allows for the production of substantial amounts of RNA beyond initial research requirements. The collaboration also sets the stage for potential scale-up as the program advances.

Alison Moore, the President and CEO of Codexis, expressed enthusiasm about this new collaboration. "We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity," she stated. The engagement not only supports Codexis's growth strategy but also exemplifies their commitment to fostering partnerships that drive innovation in therapeutics manufacturing.

Future Prospects in RNA Manufacturing

As the demand for RNA therapies rises, Codexis is primed to capitalize on this burgeoning market. The company is currently leveraging its CodeEvolver® technology platform to discover and enhance enzymes that facilitate nucleic acid synthesis and small molecule pharmaceuticals manufacturing. These advancements will allow Codexis to improve yield, reduce energy consumption, and minimize waste. Through the ECO Synthesis Manufacturing Platform, they aim to provide better production efficiencies, which is crucial for the future of RNA therapeutics.

This agreement highlights a forward-thinking strategy by Codexis to not only expand its operational capabilities but also to position itself at the forefront of RNA therapeutic development. As they embark on this venture, it is clear that the collaboration will potentially lead to significant breakthroughs in treating cardiovascular diseases.

For more information about Codexis and its innovative solutions, visit codexis.com.